Welcome to our dedicated page for Steris news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris stock.
STERIS plc provides healthcare and life sciences products and services that support patient care, with an emphasis on infection prevention. Its recurring news includes financial results and outlook updates for continuing operations, quarterly dividend actions, conference-call announcements, and board or executive governance changes.
The company’s business updates center on sterilization services, Applied Sterilization Technologies, sterilizers, washer-disinfectors, and decontamination equipment and supplies used by care providers and biopharma manufacturing sites. Corporate announcements also address capital spending, cash flow expectations, and shareholder distribution information.
STERIS (NYSE: STE) reported fiscal 2027 first quarter revenue of $1.5 billion, up 7% year over year, with constant currency organic revenue growth of 6%. As reported diluted EPS rose to $2.04 from $1.79, while adjusted EPS increased to $2.59 from $2.34.
Healthcare revenue grew 8% to $1.05 billion, AST rose 6% to $297.6 million, and Life Sciences increased 9% to $146.7 million. Operating income improved across all segments. Net cash from operations declined to $367.1 million and free cash flow to $279.6 million, mainly due to lower working capital contribution.
STERIS announced a targeted restructuring tied to consolidating formulated chemistries into a new North Carolina Center of Excellence, expecting $55–$70 million pre-tax charges through fiscal 2030 and eventual closure of facilities in Missouri and Minnesota. The company reaffirmed fiscal 2027 guidance for 7–8% reported revenue growth, 6–7% constant currency organic growth, and adjusted EPS of $11.10–$11.30. Capital expenditures are now projected at $450 million and free cash flow at about $800 million.
STERIS (NYSE: STE) will invest $600 million to build a formulated chemistries manufacturing and distribution Center of Excellence in North Carolina near the Raleigh-Durham Research Triangle. The 600,000 square-foot campus will produce infection prevention and contamination control chemistries for Healthcare and Pharmaceutical customers.
The project will be constructed in phases and is expected to become operational in 2–3 years, beginning with distribution. According to STERIS, the site will ultimately replace existing chemistries manufacturing and distribution operations in St. Louis, Missouri and Plymouth, Minnesota and create about 335 jobs in North Carolina.
STERIS (NYSE: STE) declared a quarterly interim dividend of $0.69 per share, a $0.06 increase from its prior level and marking the Company’s 21st consecutive year of dividend growth. The dividend will be paid on September 25, 2026 to shareholders of record as of September 4, 2026. Additional details on U.S. tax treatment, including Forms 8937, are available on the Company’s investor relations website.
STERIS (NYSE: STE) will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET on August 6, 2026. The call is accessible via webcast at www.steris-ir.com or by U.S. and international dial-in numbers with operator assistance.
A press release with detailed results will be issued after the U.S. market closes on August 5, 2026. A replay will be available from 12:00 p.m. ET on August 6, 2026 online and by phone using access code 9090649.
STERIS (NYSE: STE) reported fiscal 2026 revenue from continuing operations up 9% to $5.9 billion, with constant currency organic growth of 7%. Diluted EPS from continuing operations rose to $7.93, and adjusted EPS increased to $10.17. Free cash flow reached $982.9 million.
For fiscal 2027, STERIS expects revenue growth of 7–8% and adjusted EPS of $11.10–$11.30. The Board approved a new $1 billion share repurchase program and plans about $375 million in capital expenditures, including a new Mentor, Ohio manufacturing plant.
STERIS (NYSE: STE) appointed Pierre Boulud to its Board of Directors effective May 5, 2026. Boulud is CEO of bioMérieux since 2023 and previously served as bioMérieux COO and head of Asia Pacific; he spent 14 years at Ipsen and earlier worked at Boston Consulting Group.
The company emphasized his leadership, global perspective, strategic acumen, and operational expertise as reasons for the appointment.
STERIS (NYSE: STE) announced a quarterly dividend of $0.63 per share. The dividend is payable on June 26, 2026 to shareholders of record at the close of business on June 8, 2026. The company provides U.S. tax guidance and Forms 8937 on its investor website.
Contact: Julie Winter, Vice President, Investor Relations and Corporate Communications.
STERIS (NYSE: STE) will host a conference call to discuss fiscal 2026 fourth quarter and full year results at 9:00 a.m. ET on May 12, 2026.
A press release with financial results will be issued after U.S. market close on May 11, 2026. Live webcast and replay details, phone numbers, and access codes are provided for investor access.
Teleflex (NYSE:TFX) announced Board and governance changes on April 9, 2026, including the nomination of Michael J. Tokich as an independent director and the appointment of Andrew A. Krakauer as Chairman effective after the 2026 Annual Meeting.
The Board will form a Growth and Operating Committee to support transformation efforts, and the company plans to commence opportunistic share repurchases under its existing $1 billion authorization beginning in Q2 2026, subject to market conditions and cash flow needs.
STERIS (NYSE: STE) reported fiscal 2026 third-quarter continuing‑operations revenue of $1.5 billion, up 9% year‑over‑year, with constant currency organic growth of 8%. As‑reported EPS was $1.96; adjusted EPS was $2.53. Nine‑month free cash flow reached $737.6 million. Fiscal 2026 outlook was maintained, with adjusted EPS guidance of $10.15–$10.30 and revenue growth of 8–9%.